XT-150 intrathecal / Xalud Therap - LARVOL DELTA

XT-150-1-0402: Safety Study of XT-150 in Participants With ALS (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Xalud Therapeutics, Inc. | Trial completion date: Mar 2027 ➔ Jun 2028 | Trial primary completion date: Mar 2027 ➔ Jun 2028

Biomarker • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

XT-150-1-0402: Safety Study of XT-150 in Participants With ALS (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Xalud Therapeutics, Inc. | Trial completion date: Jun 2026 ➔ Mar 2027 | Initiation date: Feb 2025 ➔ Nov 2025 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

XT-150-1-0402: Safety Study of XT-150 in Participants with ALS (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Xalud Therapeutics, Inc.

Biomarker • New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • CRP

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Xalud Therapeutics, Inc. | N=32 ➔ 5 | Trial completion date: Apr 2023 ➔ Sep 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2023 ➔ Sep 2022; Failure to enroll a sufficient number of patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Neuralgia • Pain • IL10

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Xalud Therapeutics, Inc. | N=48 ➔ 32

Enrollment change • Neuralgia • Pain • IL10

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Xalud Therapeutics, Inc.; Trial completion date: Sep 2022 ➔ Apr 2023; Trial primary completion date: Aug 2022 ➔ Jan 2023

Clinical • Trial completion date • Trial primary completion date • Neuralgia • Pain • MRI

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Xalud Therapeutics, Inc.; Trial completion date: Dec 2021 ➔ Sep 2022; Trial primary completion date: Jul 2021 ➔ Aug 2022

Clinical • Trial completion date • Trial primary completion date • Neuralgia • Pain • Peripheral Neuropathic Pain • MRI

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Xalud Therapeutics, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Oct 2020 ➔ Jan 2021; Trial primary completion date: Apr 2021 ➔ Jul 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Neuralgia • Pain • Peripheral Neuropathic Pain

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=270; Recruiting; Sponsor: Xalud Therapeutics, Inc.; Trial completion date: Sep 2021 ➔ Feb 2022

Clinical • Trial completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Xalud Therapeutics, Inc.; Trial primary completion date: Jan 2021 ➔ Apr 2021

Clinical • Trial primary completion date • Neuralgia • Pain

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Xalud Therapeutics, Inc.

Clinical • New P1 trial • Neuralgia • Pain